drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
A chimeric anti-CD20 monoclonal antibody that depletes CD20+ B cells via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis, thereby reducing pathogenic autoantibodies (e.g., anti-PLA2R/THSD7A) and downstream complement-mediated podocyte injury in idiopathic membranous nephropathy.
nci_thesaurus_concept_id
C1702
nci_thesaurus_preferred_term
Rituximab
nci_thesaurus_definition
A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)
drug_mesh_term
Rituximab
drug_category
CYTOTOXIC ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Chimeric anti-CD20 monoclonal antibody that binds CD20 on B cells and depletes them via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis, reducing pathogenic autoantibodies and downstream complement-mediated tissue injury.
drug_name
Rituximab
nct_id_drug_ref
NCT05914155